Articles
By Chase Doyle
Because of the complexity of biosimilar regulations, a pharmaceutical and therapeutics committee—which includes pharmacists and physicians—is recommended to determine appropriate biosimilar use... Read More ›
By Chase Doyle
The expanding availability of oral drugs for the treatment of a number of tumor types has increased their use as chemotherapy. Read More ›
The annual meetings of the American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS) took place in December 2014, attracting US and international oncologists interested in the latest research on basic science and clinical medicine. These are a selection of highlights from these meetings. Read More ›
By Wayne Kuznar
Two programmed cell death receptor-1 (PD-1) inhibitors—the investigational drug nivolumab and the recently approved pembrolizumab (Keytruda)—produced dramatic responses in patients with Hodgkin lymphoma in phase 1 clinical trials. Read More ›
The Third Annual World Cutaneous Malignancies Congress (WCMC) took place in San Francisco, CA, on October 30-31, 2014. Read More ›
By Phoebe Starr
The results of a phase 1b study of the combination of venetoclax plus rituximab (Rituxan) showed encouraging safety and excellent activity in patients with chronic lymphocytic leukemia (CLL). Read More ›
Why is financial planning important? The term financial planning can be used to illustrate many things. It can be a comprehensive plan, focusing on several needs or goals simultaneously, or limited to specific areas such as establishing a budget, or saving for a home, a child’s education, or retirement. Read More ›
By Phoebe Starr
Cancer-related cachexia is a debilitating condition that has had no effective treatment thus far. Its symptoms include loss of lean body mass, as well as muscle wasting and loss of appetite. Read More ›
By Wayne Kuznar
The cost of medical innovation, in particular, a fair price for new cancer medicines, is a complex topic that requires urgent attention, said speakers at a special symposium at the 2014 American Society of Hematology meeting. Read More ›
By Phoebe Starr
Early posttransplant consolidation with brentuximab vedotin (Adcetris) significantly improved progression-free survival (PFS) compared with placebo in patients with Hodgkin lymphoma who are at risk for disease progression in the placebo-controlled phase 3 AETHERA trial. Read More ›